Alkermes Plc, 8AK:FRA profile

Price (EUR)26.60
Today's Change-0.40 / -1.48%
Shares traded35.00
1 Year change+14.66%
Beta--

Data delayed at least 15 minutes, as of Nov 08 2024 07:20 GMT.

More ▼

Add to Your Portfolio

Name

Currency

Profile data is unavailable for this security.

About the company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Revenue in USD (TTM)1.51bn
Net income in USD502.58m
Incorporated2011
Employees2.10k

Location
Alkermes PlcConnaught House1 Burlington Road, Dublin 4DUBLIN D04 C5Y6IrelandIRL
Phone+353 17728000
Websitehttps://www.alkermes.com/

More ▼

Income statement (USD)

Year on year Alkermes Plc grew revenues 49.61% from 1.11bn to 1.66bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 158.27m to a profit of 355.76m.

Explore our tools

Growth CalculatorBETA
Explore the time value of money, the impact of regular contributions, and the power of saving over longer timeframes
Alerts
Create detailed alerts and get notified the moment an event happens
Watchlists
Monitor a select list of assets
Are you sure you want to cancel?
Portfolio
See how trades would have performed from years past or start from the present
Data archive
Download PDF copies of reports from the newspaper markets data page
World markets
View the performance of global markets and browse news items by region
Equities screener
Find companies based on country, sector, and other equity characteristics
Funds overview
View funds that move the market, screen for funds and read relevant news

Data Provided by LSEG

All markets data located on FT.com is subject to the FT Terms & Conditions

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Alkermes Plc

Select symbol

Alkermes Plc

ApplyActions

Your alerts

About the company